"An average 1,363 cases of clinical malaria were prevented over four years of follow-up for every 1,000 children vaccinated, and 1,774 cases in those who also received a booster shot. Over three years of follow-up, an average 558 cases were averted for every 1,000 infants vaccinated, and 983 cases in those also given a booster dose."
The first malaria vaccine candidate to reach phase-3 of clinical testing was found to partially protect children against the disease up to four years after vaccination and may be available by as early as October this year, scientists reported.
The results suggest that the vaccine candidate RTS,S/AS01 could prevent a substantial number of cases of clinical malaria, especially in areas of high transmission.
"The European Medicines Agency (EMA) will assess the quality, safety, and efficacy of the vaccine based on these final data," said corresponding author Brian Greenwood, professor at the London School of Hygiene & Tropical Medicine in Britain.
"If the EMA gives a favourable opinion, WHO (World Health Organization) could recommend the use of RTS,S/AS01 as early as October this year. If licensed, RTS,S/AS01 would be the first licensed human vaccine against a parasitic disease," Greenwood added.
For more info:
http://www.business-standard.com/article/news-ians/first-malaria-vaccine-likely-by-october-scientists-115042700494_1.html